Welcome to our dedicated page for Centessa Pharmaceuticals plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Centessa Pharmaceuticals plc filings document the regulatory record of a clinical-stage pharmaceutical issuer with American Depositary Shares listed on Nasdaq, each representing one ordinary share. Disclosures cover its orexin receptor 2 (OX2R) agonist focus, operating and financial results, corporate presentations, risk and capital-structure matters, and securities registered in connection with the ADS program.
Centessa's SEC filings also include Form 8-K material-event reports for underwriting and at-the-market sales agreements, public offerings of ADSs, executive and board changes, employment and advisory arrangements, and Regulation FD materials. Proxy filings describe governance, shareholder voting matters, compensation topics, and related public-company controls.
Pentwater Capital Management LP and Matthew Halbower report that they no longer beneficially own any ordinary shares of Centessa Pharmaceuticals plc, represented by ADSs with CUSIP 152309100. Their reported beneficial ownership is 0 shares and 0% of the class, with no sole or shared voting or dispositive power. The filing confirms they now fall under the category of ownership of 5 percent or less of this class of Centessa securities.
Centessa Pharmaceuticals plc received an amended beneficial ownership report from Index Ventures Life VI (Jersey) L.P., Yucca (Jersey) SLP, and Index Venture Life Associates VI Ltd. As of June 30, 2026, these reporting persons collectively report beneficial ownership of 0 Ordinary Shares of Centessa, representing 0.0% of the outstanding class. They report no sole or shared voting power and no sole or shared dispositive power over any Ordinary Shares.
Centessa Pharmaceuticals plc received an updated Schedule 13G/A from Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross reporting that they no longer beneficially own any ordinary shares or related American Depositary Shares of the company. Each reporting person lists 0 shares beneficially owned and a 0.0% ownership stake, with no sole or shared voting or dispositive power. The amendment confirms that their holdings have fallen to five percent or less of the class.
Centessa Pharmaceuticals plc is the subject of an amended Schedule 13G filing in which a group of affiliated investment entities managed by Medicxi report their current ownership position. The filing covers several Jersey-based limited partnerships and limited companies, collectively referred to as the Medicxi Funds and related managing entities.
As of June 30, 2026, the Reporting Persons state that they beneficially own 0 Ordinary Shares of Centessa Pharmaceuticals plc, representing 0.0% of the outstanding class. They also report having no sole or shared power to vote or dispose of any Ordinary Shares. The certification section is executed on behalf of each Reporting Person by Francois Chesnay in various director and manager capacities.
FMR LLC files Amendment No. 4 to a Schedule 13G/A reporting ownership of 1,800 shares of Centessa Pharmaceuticals plc common stock. The filing lists the CUSIP 152309100, shows 1,800 shares beneficially owned representing 0.0% of the class, and names Abigail P. Johnson in the cover responses. Signatures are dated 07/07/2026.
Farallon Capital Management and related reporting persons have fully exited their position in Centessa Pharmaceuticals plc. In this Amendment No. 1 to their Schedule 13D, they report beneficial ownership of 0 ordinary shares and 0% of the class. The change reflects their disposal of all previously reported Centessa ordinary shares on June 24, 2026, in connection with the closing of Eli Lilly and Company’s acquisition of all outstanding Centessa ordinary shares through its wholly owned subsidiary LDH XV Corporation, as described in Centessa’s Form 8-K.
Farallon Capital Management and related individuals report beneficial ownership of 9,370,093 Centessa Pharmaceuticals ordinary shares, equal to 6.1% of the class based on 154,731,309 shares outstanding as of June 10, 2026. The stake, held through several Farallon investment partnerships via American Depositary Shares, reflects an approximate aggregate investment cost of $325,995,909. The group describes Centessa as an attractive investment and may buy more shares, sell, hedge, or take other actions over time to maximize the value of its position, while stating it has no specific corporate-change plans beyond what is outlined in the filing.
Medicxi Ventures Management (Jersey) Ltd reported open-market sale transactions in this Form 4 filing.
Centessa Pharmaceuticals plc disclosed that investment entities affiliated with Medicxi completed the transfer of a total of 19,963,157 Ordinary Shares in connection with the acquisition of Centessa by Eli Lilly and Company. The transfer occurred automatically at the effective time of a UK Scheme of Arrangement, not through discretionary open-market trading by the reporting entities.
Under the deal, each Ordinary Share (and each ADS representing one Ordinary Share) entitled holders to receive $38.00 in cash per share, plus one non-transferable contingent value right for potential additional payments of up to $9.00 per share upon achievement of specified milestones. Following these transactions, the reported Medicxi-related holdings of Centessa Ordinary Shares decreased to zero, and the reporting persons note they disclaim beneficial ownership except to the extent of any pecuniary interest.
INDEX VENTURES LIFE VI (JERSEY) L.P. reported open-market sale transactions in this Form 4 filing.
Centessa Pharmaceuticals plc reported that investment entities associated with Index Ventures completed the transfer of 9,961,789 Ordinary Shares in connection with the company’s acquisition by Eli Lilly and Company. The shares, held indirectly through Index Ventures Life VI (Jersey) L.P. and Yucca (Jersey) SLP, moved automatically at the effective time of a UK Scheme of Arrangement, rather than through a discretionary market trade.
At the effective time, each Ordinary Share became entitled to receive $38.00 in cash per share, plus one non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share, subject to specified milestones. The reporting persons disclaim beneficial ownership of these securities except to the extent of any pecuniary interest.